Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence
of antiphospholipid antibodies (aPL)(lupus anticoagulant, anticardiolipin antibodies and anti …

The prognosis in systemic lupus erythematosus (SLE) has improved due to better treatment
and care, but cardiovascular disease (CVD) still remains an important clinical problem, since …

Objective This study aimed to use cluster analysis (CA) to identify different clinical
phenotypes among antiphospholipid antibodies (aPL)-positive patients. Methods The …

Neuropsychiatric systemic lupus erythematosus (NPSLE) has a broad spectrum of subtypes
with diverse severities and prognoses. Ischemic and inflammatory mechanisms, including …

Objective Studies show that generic cardiovascular risk (CVR) prediction tools may
underestimate CVR in SLE. We examined, for the first time to our knowledge, whether …

Systemic lupus erythematosus (SLE) patients display an increased risk of cardiovascular
disease (CVD). With the improved clinical management of other classical severe …

Currently, the guidelines for the prevention of atherosclerosis in patients with
antiphospholipid syndrome (APS) do not differ substantially from those in the general …

Objectives Cardiovascular disease is a major cause of morbidity and mortality in
Antiphospholipid syndrome (APS). Arterial stiffness (ArS) has emerged as a predictor of …

Update on the pathogenesis of central nervous system lupus : Current Opinion in
Rheumatology Update on the pathogenesis of central nervous system lupus : Current …

Background Systemic lupus erythematosus (SLE), is characterized by a systemic
involvement including myocardial dysfunction. Being standard echocardiography not able at …